{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:20:40Z","timestamp":1790889640192,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T00:00:00Z","timestamp":1399248000000},"content-version":"vor","delay-in-days":1526,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1593\/neo.91880","type":"journal-article","created":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T13:08:04Z","timestamp":1429794484000},"page":"275-283","source":"Crossref","is-referenced-by-count":64,"title":["The Thrombospondin-1 Mimetic ABT-510 Increases the Uptake and Effectiveness of Cisplatin and Paclitaxel in a Mouse Model of Epithelial Ovarian Cancer"],"prefix":"10.1016","volume":"12","author":[{"given":"Nicole E.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Greenaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Henkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Moorehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1593\/neo.91880_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1593\/neo.91880_bib2","first-page":"5","article-title":"World Health Organization classification and nomenclature of ovarian cancer","volume":"42","author":"Scully","year":"1975","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1593\/neo.91880_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1098-2388(200007\/08)19:1<3::AID-SSU2>3.0.CO;2-S","article-title":"Ovarian cancer: epidemiology, biology, and prognostic factors","volume":"19","author":"Holschneider","year":"2000","journal-title":"Semin Surg Oncol"},{"key":"10.1593\/neo.91880_bib4","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"9","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1593\/neo.91880_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005343.pub2","article-title":"Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer","author":"Morrison","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1593\/neo.91880_bib6","series-title":"Principles and Practice of Gynecologic Oncology","first-page":"919","article-title":"Epithelial ovarian cancer","author":"Ozols","year":"1997"},{"key":"10.1593\/neo.91880_bib7","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/0008-5472.CAN-04-2427","article-title":"Endogenous inhibitors of angiogenesis","volume":"65","author":"Nyberg","year":"2005","journal-title":"Cancer Res"},{"key":"10.1593\/neo.91880_bib8","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1073\/pnas.87.17.6624","article-title":"A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin","volume":"87","author":"Good","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1593\/neo.91880_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1535-7163.MCT-08-0864","article-title":"ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer","volume":"8","author":"Greenaway","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1593\/neo.91880_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.coc.0000256104.80089.35","article-title":"A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma","volume":"30","author":"Markovic","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1593\/neo.91880_bib11","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1200\/JCO.2008.17.4706","article-title":"Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma","volume":"26","author":"Baker","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.91880_bib12","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1002\/cncr.23953","article-title":"A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer","volume":"113","author":"Gordon","year":"2008","journal-title":"Cancer"},{"key":"10.1593\/neo.91880_bib13","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1158\/1078-0432.CCR-07-1477","article-title":"Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma","volume":"13","author":"Ebbinghaus","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1593\/neo.91880_bib14","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1200\/JCO.2005.05.013","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer","volume":"23","author":"Hoekstra","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.91880_bib15","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/annonc\/mdl102","article-title":"A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors","volume":"17","author":"Gietema","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1593\/neo.91880_bib16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejca.2005.08.040","article-title":"Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination","volume":"42","author":"Hoekstra","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1593\/neo.91880_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-0-387-68969-2_14","article-title":"Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax","volume":"622","author":"Roby","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1593\/neo.91880_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2007.10.035","article-title":"Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer","volume":"108","author":"Greenaway","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1593\/neo.91880_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1005835212246","article-title":"The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor","volume":"37","author":"Straathof","year":"1998","journal-title":"J Neurooncol"},{"key":"10.1593\/neo.91880_bib20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00000658-197203000-00014","article-title":"Anti-angiogenesis: new concept for therapy of solid tumors","volume":"175","author":"Folkman","year":"1972","journal-title":"Ann Surg"},{"key":"10.1593\/neo.91880_bib21","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.1158\/1078-0432.CCR-08-0243","article-title":"Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model","volume":"14","author":"Mabuchi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1593\/neo.91880_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ygyno.2008.08.011","article-title":"Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer","volume":"111","author":"Richardson","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1593\/neo.91880_bib23","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2007.10.8332","article-title":"Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity","volume":"26","author":"Azad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.91880_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2008.02.009","article-title":"Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II consortia","volume":"110","author":"Nimeiri","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1593\/neo.91880_bib25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)10261-1","article-title":"Screening for ovarian cancer: a pilot randomised controlled trial","volume":"353","author":"Jacobs","year":"1999","journal-title":"Lancet"},{"key":"10.1593\/neo.91880_bib26","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1158\/1535-7163.MCT-08-0715","article-title":"Combination of antiangiogenesis with chemotherapy for more effective cancer treatment","volume":"7","author":"Ma","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1593\/neo.91880_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1593\/neo.91880_bib28","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.1125950","article-title":"Antiangiogenic therapy: a universal chemosensitization strategy for cancer?","volume":"312","author":"Kerbel","year":"2006","journal-title":"Science"},{"key":"10.1593\/neo.91880_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"key":"10.1593\/neo.91880_bib30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1593\/neo.91880_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminoncol.2006.03.011","article-title":"Systemic therapy for ovarian cancer: current status and new treatments","volume":"33","author":"Ozols","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1593\/neo.91880_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/416279b","article-title":"Tumour biology\u2014herceptin acts as an anti-angiogenic cocktail","volume":"416","author":"Izumi","year":"2002","journal-title":"Nature"},{"key":"10.1593\/neo.91880_bib33","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.bjc.6604352","article-title":"Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib","volume":"98","author":"Bocci","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1593\/neo.91880_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/0008-5472.CAN-06-3282","article-title":"Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer","volume":"67","author":"Kamat","year":"2008","journal-title":"Cancer Res"},{"key":"10.1593\/neo.91880_bib35","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1073\/pnas.2135406100","article-title":"Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy","volume":"100","author":"Bocci","year":"2003","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147655861080106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147655861080106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T07:28:17Z","timestamp":1537687697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147655861080106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S147655861080106X"],"URL":"https:\/\/doi.org\/10.1593\/neo.91880","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}